Last reviewed · How we verify
NCT03698812
A Multicenter Prospective Cohort Study on the Clinical Prognosis of Ulcerative Colitis
trial testing Colonoscope in Prospective Study in 9 participants. Status unknown.
30 September 2020
Quick facts
| Lead sponsor | Nanfang Hospital, Southern Medical University |
|---|---|
| Status | Status unknown |
| Study type | OBSERVATIONAL |
| Enrollment | 9 |
| Start date | 1 January 2017 |
| Primary completion | 30 September 2020 |
| Estimated completion | 30 September 2021 |
| Sites | 1 location across China |
Drugs / interventions tested
- Colonoscope
Conditions studied
- Prospective Study — all drugs for Prospective Study →
- Ulcerative Colitis in Remission — all drugs for Ulcerative Colitis in Remission →
Sponsor
Nanfang Hospital, Southern Medical University
Who can join
Adults 14 to 75, any sex, with Prospective Study or Ulcerative Colitis in Remission. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Mucosal healing or histological remission is an important target for the treatment of inflammatory bowel disease. In this study, patients with mucosal healing are defined as a control group, observing their clinical outcomes for 3 years, and describing the recurrence rate. The secondary objective is to study the operative rate, glucocorticoid utilization rate, treatment escalation rate, hospitalization rate and incidence of related complications.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT03698812
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Colonoscope
Trials testing the same drug.
- NCT06371183 — A Comparative Study of Clinical, Endoscopic and Histopathological Features of Colitis in Children · NA · not yet recruiting
Other recruiting trials for Prospective Study
Currently open trials in the same condition.
- NCT07243561 — Prospective Clinical Study on Human Umbilical Cord Mesenchymal Stem Cell-Derived Exosomes for the Treatment of Childhood · Phase 1, PHASE2 · recruiting
- NCT07048561 — Health-related Physical Fitness and Executive Function in Older Adults: A Prospective Study · recruiting
- NCT07384676 — Environmental and Behavioral Factors in Infertility and ART Outcomes · recruiting
Other Nanfang Hospital, Southern Medical University trials
Trials by the same sponsor.
- NCT07091994 — A Trial of Edaravone Dexborneol in Acute Ischemic Stroke With Active Malignancy · Phase 4 · not yet recruiting
- NCT06444022 — hAESCs Prevent Acute Graft-versus-host Disease After Hematopoietic Stem Cell Transplantation · Phase 1 · withdrawn
- NCT07537777 — Benmelstobart Plus Anlotinib Combined With SBRT for Patients With Hepatocellular Carcinoma Failing First-Line Targeted T · Phase 2 · not yet recruiting
- NCT07481032 — Effect of Fufang Biejiaruangan Combined With Antiviral Therapy on the Incidence of Hepatocellular Carcinoma in Patients · NA · not yet recruiting
- NCT07511894 — Beta-Blockers on the Efficacy of Neoadjuvant Immunotherapy for Gastric Cancer · Phase 2 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03698812 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Nanfang Hospital, Southern Medical University
- Last refreshed: 17 October 2018
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03698812.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing